Strand Therapeutics

Strand Therapeutics is an early-stage biotechnology company based in Boston, Massachusetts, founded in 2017 by biological engineers from the MIT Synthetic Biology Center. With a team of 99 employees, the company specializes in developing programmable mRNA therapeutics that utilize synthetic biology and engineering principles. Strand focuses on creating autonomous mRNA medicines designed for precise, cell-type-specific protein expression. Their innovative mRNA programming language incorporates logic circuits, allowing for controlled protein activity in terms of location, timing, intensity, and duration. This technology aims to enhance the safety and efficacy of mRNA therapies, particularly in oncology, where their initial programs target solid tumors. Strand's approach includes self-replicating mRNAs for sustained protein expression and long-acting therapies intended to replace chronic treatments with single-dose, curative options. The company actively seeks partnerships to advance its mission of precision medicine in oncology and immunotherapy.